Pancreatic Cancer Research

ResearcherSecond Military Medical UniversityNo recent work listed

Zhao‐Shen Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1650-4014; OpenAlex author ID A5100733346. Sources: OpenAlex.

Their work

Papers
25 (first author 0, last author 13)
Trials
0
Grants
0
Labs led
1
Collaborators
70
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 6 papers · 2014: 2 papers · 2015: 4 papers · 2016: 1 paper · 2017: 5 papers · 2018: none · 2019: 2 papers · 2020: 2 papers

Papers 25

  1. Study of underlying pancreatic cancer could be improved. Co-author DOI 10.1016/j.hpb.2019.12.015↗
  2. Downregulation of miR-486-5p Enhances the Anti-Tumor Effect of 5-Fluorouracil on Pancreatic Cancer Cells. Last author DOI 10.2147/ott.s231153↗
  3. Design flaws in statins and pancreatic cancer research. Co-author DOI 10.1002/ijc.32352↗
  4. miR-205 targets runt-related transcription factor 2 to inhibit human pancreatic cancer progression. Last author DOI 10.3892/ol.2018.9689↗
  5. Proteasome activator subunit 3 promotes pancreatic cancer growth via c-Myc-glycolysis signaling axis. Last author DOI 10.1016/j.canlet.2016.08.018↗
  6. Incidence of and risk factors for pancreatic cancer in chronic pancreatitis: A cohort of 1656 patients. Co-author DOI 10.1016/j.dld.2017.07.001↗
  7. RE: Influence of Statins and Cholesterol on Mortality Among Patients With Pancreatic Cancer. Co-author DOI 10.1093/jnci/djx102↗
  8. STK33 Promotes Growth and Progression of Pancreatic Cancer as a Critical Downstream Mediator of HIF1α. Co-author DOI 10.1158/0008-5472.can-17-0067↗
  9. Exploring brusatol as a new anti-pancreatic cancer adjuvant: biological evaluation and mechanistic studies. Co-author DOI 10.18632/oncotarget.17761↗
  10. Bulk pancreatic cancer cells can convert into cancer stem cells(CSCs) in vitro and 2 compounds can target these CSCs. Last author DOI 10.1080/15384101.2015.1127471↗
  11. Pancreatic cancer in patients with recently diagnosed chronic pancreatitis. Last author DOI 10.1038/ajg.2015.107↗
  12. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo. Co-author DOI 10.1371/journal.pone.0144969↗
  13. ZIP4 silencing improves bone loss in pancreatic cancer. Co-author DOI 10.18632/oncotarget.4667↗
  14. GSH2 promoter methylation in pancreatic cancer analyzed by quantitative methylation-specific polymerase chain reaction. Co-author DOI 10.3892/ol.2015.3241↗
  15. Chronic pancreatitis and pancreatic cancer. Last author DOI 10.1053/j.gastro.2014.03.054↗
  16. Downregulation of L1CAM inhibits proliferation, invasion and arrests cell cycle progression in pancreatic cancer cells in vitro. Co-author DOI 10.3892/etm.2014.1519↗
  17. Expression of NEDD9 in pancreatic ductal adenocarcinoma and its clinical significance. Last author DOI 10.1007/s13277-012-0624-8↗
  18. DLC-1 is a candidate biomarker methylated and down-regulated in pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s13277-013-0846-4↗
  19. Viral therapy for pancreatic cancer: tackle the bad guys with poison. Last author DOI 10.1016/j.canlet.2013.01.035↗
  20. Effect of Photofrin-mediated photocytotoxicity on a panel of human pancreatic cancer cells. Co-author DOI 10.1016/j.pdpdt.2012.11.001↗
  21. Aberrant microRNAs expression patterns in pancreatic cancer and their clinical translation. Last author DOI 10.1089/cbr.2012.1389↗
  22. Aberrant DNA methyltransferase expression in pancreatic ductal adenocarcinoma development and progression. Last author DOI 10.1186/1756-9966-32-86↗
  23. CEA promoter-regulated oncolytic adenovirus-mediated Hsp70 expression in immune gene therapy for pancreatic cancer. Last author DOI 10.1016/j.canlet.2012.01.009↗
  24. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Co-author DOI 10.1373/clinchem.2011.172767↗
  25. Pancreatic cancer incidence and outcome in relation to ABO blood groups among Han Chinese patients: a case-control study. Last author DOI 10.1002/ijc.25426↗

Closest collaborators

The 25 strongest of 70 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Liang‐Hao Hu · 5 shared papers, 2014–2020 · strength 0.48
  2. Jun Gao · 4 shared papers, 2013–2016 · strength 0.20
  3. Bai‐Rong Li · 3 shared papers, 2014–2017 · strength 0.20
  4. Yiqi Du · 4 shared papers, 2012–2017 · strength 0.19
  5. Hongyu Wu · 3 shared papers, 2013–2017 · strength 0.16
  6. Tao Zhang · 1 shared paper, 2020 · strength 0.15
  7. Liu Yu · 1 shared paper, 2020 · strength 0.15
  8. Qiwen Ben · 3 shared papers, 2011–2016 · strength 0.14
  9. Lu Zhuang · 1 shared paper, 2019 · strength 0.14
  10. Yu Liu · 1 shared paper, 2019 · strength 0.14
  11. Wei Wang · 1 shared paper, 2020 · strength 0.12
  12. Bowei Liu · 1 shared paper, 2020 · strength 0.12
  13. Shuangyin Han · 1 shared paper, 2020 · strength 0.12
  14. Yaozong Yuan · 3 shared papers, 2011–2014 · strength 0.11
  15. Muyun Liu · 1 shared paper, 2017 · strength 0.09
  16. Weiqin Lu · 1 shared paper, 2017 · strength 0.09
  17. Zheng Lu · 1 shared paper, 2017 · strength 0.08
  18. Zhengquan Lai · 1 shared paper, 2017 · strength 0.08
  19. Zhi‐Xiu Lin · 1 shared paper, 2017 · strength 0.08
  20. Po Sing Leung · 1 shared paper, 2017 · strength 0.08
  21. Can Xu · 2 shared papers, 2012–2013 · strength 0.08
  22. Changqing Su · 2 shared papers, 2012–2013 · strength 0.08
  23. Jiefang Guo · 1 shared paper, 2017 · strength 0.08
  24. Jun Hao · 1 shared paper, 2017 · strength 0.08
  25. Yuzheng Xue · 2 shared papers, 2013 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.